Recent work shows that transcriptomic biomarkers can identify subgroups responding to combinatorial BRAF+MEK inhibitor treatment (Wongchenko et al, 2017), but for those 50–60% of melanoma patients without BRAFV600E/K mutation, other suitable therapies are needed. Here, BRAF is linked to melanoma.